Allogeneic Bone Marrow Transplantation (BMT) for Chronic Myelogeneous Leukemia (CML) in Chronic Phase (CP)
Part of the
book series (HEMATOLOGY)
Allogeneic u4r seems to be a promising therapeutic modality for patients with CML. An actuarial 3-years disease-free survival of 60–70% can be achieved in patients grafted during CP of the disease (1, 2, 3). The results of BMT in accelerated phase and blastic phase of CML are poorer then in CP; the major problems are due to transplant-related complications (2) or to increased frequency of recurrent leukemia (3). This report summarizes the experience with allogeneic BMT performed during CP of CML at the Institute of Hematology of the University of Rame.
KeywordsBone Marrow Transplantation Chronic Phase Chronic Myelogeneous Leukemia Allogeneic Bone Marrow Transplantation Accelerate Phase
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Champlin R.E. and Gale R.P.: Cancer Treat. Rep. 68: 145–161, 1984PubMedGoogle Scholar
Goldman J.M. et al.: Exp. Hamatol. 12 (supp1.15): 34–35, 1984Google Scholar
Speck B. et al.: The Lancet, i: 665–668, 1984CrossRefGoogle Scholar
Papa G. et al.: New Trends in Experimental Hematology, eds. C. Peschle and C. Rizzoli, Serono Symposia Review 7:346–348, 1984Google Scholar
© Springer Science+Business Media New York 1985